Istesso Ltd (‘’Istesso’’) is pleased to announce the successful dosing of the first patients in a Phase 2a study of its investigational drug, MBS2320, for the treatment of rheumatoid arthritis (“RA”). The progression to Phase 2a follows the successful completion of dosing in a Phase 1 study and is accompanied by an expansion of the financial terms of Istesso’s 2014 Option and Licence Agreement with Janssen Biotech, Inc. (“Janssen”).
MBS2320 is a first-in-class metabolic reprogramming agent for the treatment of RA and is distinguished from existing treatments by its dual mode-of-action which not only reduces inflammation, thereby preventing the progression of disease, but may also promote bone and joint remodelling.
The progression to Phase 2a follows the analysis of data emerging from a Phase 1 trial in which MBS2320 has demonstrated good safety and tolerability in healthy volunteers, as well as predictable blood exposure levels (“pharmacokinetics”). Analysis of the data from a cohort of RA patients included in the trial is ongoing, with good safety and tolerability observed to date.
The Phase 2a study is a 12-week randomised, placebo-controlled, double-blind, multi-centre trial assessing the safety, tolerability and efficacy of MBS2320. Istesso anticipates that results will be available in late 2018.
For further information, please contact:
Dr Sam Williams, CEO +44 207 444 0066
Notes to Editors
About rheumatoid arthritis
Rheumatoid Arthritis (RA) is a chronic, progressive and disabling autoimmune disease affecting 165 million people worldwide, or one per cent of the global population. It is a painful condition that, unchecked, can cause severe disability. The disease can progress very rapidly, causing swelling and damaging cartilage and bone around the joints. Any joint may be affected but the hands, feet and wrists are most commonly involved, preventing patients from carrying out everyday tasks.
MBS2320 is a first-in-class metabolic reprogramming agent for the treatment of RA and is distinguished from existing treatments by its dual mode-of-action which not only reduces inflammation, thereby preventing the progression of disease, but may also promote bone and joint remodelling. MBS2320 is subject to an Option and Licence Agreement with Janssen Biotech Inc.
Istesso is a drug discovery and development company working in the field of immunometabolism. Istesso’s pipeline of pre-clinical and clinical assets act by reprogramming metabolism to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and multiple sclerosis. Istesso was founded in 2017 as the holding company for Modern Biosciences plc. For more information please visit www.istesso.co.uk.